title: Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
abstract: Two chemotherapeutic regimens were compared in 102 patients with metastatic breast carcinoma, randomized to either doxorubicin-cyclophosphamide (DC) or cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone (CMFVP). The objective response rates were 32 per cent in the former and 35 per cent in the latter group, the complete response rates 6.4 and 21.8 per cent, and mean duration of the remission 7.7 and 11.2 months, respectively. Most responders had multiple metastases and had received previous hormonal treatment. The DC regimen was found to be slightly more toxic than CMFVP.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate